MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation in upcoming investor and industry conferences.

Given the potential side effects of GLP-1 prescription drugs, many Utahns are seeking alternative methods to naturally boost ...

Glucagon is indicated for the treatment of severe hypoglycemia in patients with diabetes mellitus and as a diagnostic aid for ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

Exercise can dramatically lower blood glucose levels and trigger hypoglycemia in people with type 1 diabetes (T1D), even when ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Eli Lilly this week announced it has submitted applications to US and European regulatory agencies for nasal glucagon, which, if approved, could shave minutes and stress from the current method ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will ...

A new imaging approach reveals how dual agonist drugs like tirzepatide act on the pancreas and brain to regulate blood sugar and appetite.

FMP, the University of Oxford, and the University of Birmingham have developed a novel imaging approach to track how popular ...